Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399840 · ClinicalTrials.gov registry record · Phase 1
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01399840 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 33 participants.
The verdict
NCT01399840, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with either AML or MDS; Arm 2 will enroll patients with either CLL or MCL.
Interventions
- DRUG BMN 673
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-06-30 |
| Est. Completion | 2014-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01399840
The ClinicalTrials.gov registry entry for NCT01399840 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMN 673 is the first listed.
NCT01399840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01399840 about?
NCT01399840 is a clinical study titled "Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies". This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantl...
What is the current status of trial NCT01399840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2011-06-30. Estimated completion is 2014-05-31.
What interventions are being tested in trial NCT01399840?
The interventions under investigation include: BMN 673 (DRUG).
Who is sponsoring clinical trial NCT01399840?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.